However, treatment of PCa with TOP2A poisons has been shown to provide only palliative benefits and current clinical data has not yet determined the most beneficial use of targeting TOP2A in patients with advanced PCa [62, 63]. This evidence concerns the gene TOP2A and posterior cortical atrophy.